Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Seelos Therapeutics files new drug application for a Sanfilippo syndrome study

Proactive Investors Wednesday, 17 July 2019
Seelos Therapeutics Inc (NASDAQ:SEEL) is one step closer to launching a Phase 2b/3 clinical study for the treatment of Sanfilippo syndrome. The company has filed an Investigational New Drug application with the US Food and Drug Administration for a clinical study of its drug SLS-005, also known as Trehalose. Seelos is collaborating with Team Sanfilippo Foundation, a non-profit foundation formed by parents of children with the condition. The foundation provided a grant that is going towards funding the study. READ: Seelos Therapeutics receives funding grant from Team Sanfilippo Foundation The parties are also expanding the study from its original parameters. In addition to the study for patients with Sanfillipo syndrome types A and B, which are more common, Seelos is now able to offer a separate expanded access study for patients with types C and D, as well as those with A or B who don’t meet the initial entry criteria. “We are very excited to be working with Team Sanfilippo to offer this innovative therapy to these patients for whom there is no effective treatment," Seelos' Chief Medical Officer Warren Wasiewski said. “Trehalose, with its multiple mechanisms of action, has the potential to be effective in a number of neurologic diseases for which we intend to explore.” Sanfilippo syndrome is a degenerative disease that affects the central nervous system, typically in children. It is caused by a deficiency in certain enzymes involved in the degradation of sulfate. Over time, patients suffer a loss of speech and other cognitive skills, heart problems and often death prior to adulthood. Contact Andrew Kessel at [email protected]tors.com Follow him on Twitter @andrew_kessel
0
shares
ShareTweetSavePostSend
 
Credit: TomoNews US - Published < > Embed
News video: A new study uncovers bacteria'sdrug defense mechanism

A new study uncovers bacteria'sdrug defense mechanism 01:09

BIRMINGHAM / U.K — Researchers have discovered how a group of drug-resistant bacteria defend against medicine. Gram-negative bacteria have an additional outer membrane that makes them strong against antibiotics and responsible for serious drug-resistant infections. This outer membrane is made...

Recent related videos from verified sources

'I've got a second chance, it's my turn to give back.' Former opioid abusers help current addicts [Video]"I've got a second chance, it's my turn to give back." Former opioid abusers help current addicts

"I've got a second chance, it's my turn to give back." Former opioid abusers help current addicts

Credit: WKBW Buffalo     Duration: 02:29Published

What Your Sleeping Position Reveals About You [Video]What Your Sleeping Position Reveals About You

Odds are if you like "Modern Family" and call yourself an early bird — you sleep on your back, according to new research. The study examined the way respondents sleep and split respondents into three..

Credit: SWNS STUDIO     Duration: 00:59Published

How Much Would You Pay To Retrieve Stolen Data? [Video]How Much Would You Pay To Retrieve Stolen Data?

One in four people would be willing to buy back their private information from the black market, according to new research. A study of 2,000 people explored the value placed on private information..

Credit: SWNS STUDIO     Duration: 00:59Published

New Air Pollution Study [Video]New Air Pollution Study

Long-term exposure to air pollution, especially ground-level ozone, is like smoking about a pack of cigarettes a day for many years, a new study says, and like smoking, it can lead to emphysema.

Credit: KDKA CBS 2 Pittsburgh     Duration: 00:14Published


Recent related news from verified sources

Kadmon Fully Enrolls Pivotal Trial of KD025 for Chronic Graft-Versus-Host Disease

Kadmon Fully Enrolls Pivotal Trial of KD025 for Chronic Graft-Versus-Host Disease
*Company Remains on Track to Report Interim Analysis by End of 2019 * *NEW YORK, NY / ACCESSWIRE / August 13, 2019* / Kadmon Holdings, Inc. (NYSE:KDMN) today...
Accesswire

Lineage Cell Therapeutics Launches New Corporate Brand

Lineage Cell Therapeutics Launches New Corporate Brand
CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing...
Business Wire

A new prescription drug made from CBD has been groundbreaking for kids with epilepsy. We talked to their parents about the good, the bad and the ugly of what it's been like to take it.

A new prescription drug made from CBD has been groundbreaking for kids with epilepsy. We talked to their parents about the good, the bad and the ugly of what it's been like to take it.
· A new drug that's made from a component of cannabis called CBD became available in the US last year to treat rare forms of childhood epilepsy. That makes it...
Business Insider

Africa: Third New TB Drug in Over 50 Years Must Be Affordable

[MSF] Médecins Sans Frontières (MSF) welcomed today's approval by the US Food and Drug Administration (FDA) of a combination regimen containing a new drug,...
allAfrica.com

You Might Like


Other recent news in Business

Thai luxury developer says HONG KONG PROTESTS are good for salesHow APAC netizens and media are reacting to the HONG KONG protests
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.